Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block
| Autor: | Carmen Correale, Silvio Danese, Federica Furfaro, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Laura Loy, Giulia Roda, Mariangela Allocca |
|---|---|
| Přispěvatelé: | Fiorino, G, Allocca, M, Correale, C, Roda, G, Furfaro, F, Loy, L, Zilli, A, Peyrin-Biroulet, L, Danese, S |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.drug_class Clinical Biochemistry Monoclonal antibody Interleukin-23 Severity of Illness Index Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Immune system Crohn Disease Block (telecommunications) Drug Discovery Ustekinumab Interleukin 23 Humans Medicine Pharmacology business.industry medicine.disease Interleukin-12 Ulcerative colitis digestive system diseases Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Immunology Interleukin 12 Colitis Ulcerative business medicine.drug |
| Zdroj: | Expert Opinion on Biological Therapy. 20:421-427 |
| ISSN: | 1744-7682 1471-2598 |
| Popis: | Introduction: Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract. Dysregulated innate and adaptive immune pathways contribute to intestinal inflammation in IBD, and cytokines, including IL-12 and IL-23, play a key role. The blockade of both IL-12 and IL-23 may have an impact on different pathways of inflammation and could be effective for the treatment of inflammatory bowel diseases.Ustekinumab is a fully human IgG1kappa monoclonal antibody which binds to the shared p40 protein subunit of IL-12 and -23. It is currently approved for several immune-mediated diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease, and has shown promising results in UC.Areas covered: A review of the literature was performed to understand several aspects including the role of IL-12 and -23 in UC, the potential therapeutic role of ustekinumab in inflammatory bowel disease, and the positioning of ustekinumab in the therapeutic algorithm of UC, based on extrapolated data from available randomized clinical trials.Expert opinion: Ustekinumab is effective and safe in UC, and shows potential advantages compared to other drugs in moderate-to-severe UC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|